Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medivation, Astellas start Phase III study of prostate cancer drug in bid to widen use

This article was originally published in Scrip

Executive Summary

Medivation and Astellas Pharma said they have started a Phase III study of Xtandi in patients with non-metastatic castration-resistant prostate cancer, a condition for which there is no approved medicine in the US.

You may also be interested in...



Baxter's Advate helps prevent bleeding in one-year study of hemophiliacs

Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.

Mylan CEO Bresch is looking to do a sizable deal

Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.

Biogen's Scangos sees potential to dominate hemophilia market

Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.

Topics

Related Companies

UsernamePublicRestriction

Register

SC023665

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel